Overview Dividends

(NTRA) Natera - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US6323071042

Prenatal Screening, Carrier Screening, Cancer Monitoring, Transplant Assessment, Genetic Profiling

NTRA EPS (Earnings per Share)

EPS Growth (3Y CAGR): 149.85%
EPS Trend (3Y Correlation): 68.4%

NTRA Revenue

Revenue Growth (3Y CAGR): 44.00%
Revenue Trend (3Y Correlation): 99.3%

Risk via 10d forecast
Volatility	44.4%
Value at Risk 5%th	67.5%

Reward
Sharpe Ratio	1.13
Alpha	38.00

Character
Hurst Exponent	0.595
Beta	1.643

Drawdowns 3y
Max DD	39.94%
Mean DD	8.30%

Description: NTRA Natera October 16, 2025

Natera (NTRA) is a global molecular diagnostics firm that leverages next-generation sequencing to offer a portfolio of non-invasive prenatal tests (Panorama, Vistara, Horizon), hereditary cancer and carrier-screening assays (Empower, Anora), and specialty oncology and transplant monitoring tools (Signatera, Altera, Prospera, Renasight). The company also provides the cloud-based analytics platform Constellation and distributes its products through a mix of direct sales, laboratory partners, and collaborations with BGI Genomics and Foundation Medicine.

In FY 2024 Natera reported $1.03 billion in revenue, reflecting a 28 % year-over-year increase driven primarily by strong growth in its prenatal and oncology segments. The firm’s gross margin expanded to 78 % as it scaled its high-margin NIPT assays, while its cash-flow conversion improved to $180 million, underscoring the capital-efficient nature of its SaaS-enabled test platform. Key sector drivers include rising global demand for non-invasive prenatal screening-projected to exceed $5 billion by 2028-and expanding reimbursement for liquid-biopsy oncology tests, which together create a tailwind for Natera’s recurring-revenue model.

If you’re looking to deepen your valuation analysis, a quick review of ValueRay’s quantitative models for NTRA can surface hidden upside and risk factors worth exploring further.

NTRA Stock Overview

Market Cap in USD	27,544m
Sub-Industry	Biotechnology
IPO / Inception	2015-07-02
Return 12m vs S&P 500	33.9%
Analyst Rating	4.48 of 5

NTRA Dividends

Currently no dividends paid

NTRA Growth Ratios

CAGR	80.94%
CAGR/Max DD Calmar Ratio	2.03
CAGR/Mean DD Pain Ratio	9.75
Current Volume	1452.8k
Average Volume	1202.7k

Piotroski VR‑10 (Strict, 0-10) 4.5

Net Income (-309.2m TTM) > 0 and > 6% of Revenue (6% = 127.0m TTM)

FCFTA 0.04 (>2.0%) and ΔFCFTA 5.88pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 47.49% (prev 66.66%; Δ -19.16pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.07 (>3.0%) and CFO 134.9m > Net Income -309.2m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 3.27 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (137.2m) change vs 12m ago 10.84% (target <= -2.0% for YES)

Gross Margin 63.70% (prev 57.66%; Δ 6.04pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 124.1% (prev 96.29%; Δ 27.76pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -72.48 (EBITDA TTM -280.1m / Interest Expense TTM 4.37m) >= 6 (WARN >= 3)

Altman Z'' -7.89

(A) 0.55 = (Total Current Assets 1.45b - Total Current Liabilities 442.0m) / Total Assets 1.82b

(B) -1.55 = Retained Earnings (Balance) -2.82b / Total Assets 1.82b

warn (B) unusual magnitude: -1.55 — check mapping/units

(D) -4.96 = Book Value of Equity -2.82b / Total Liabilities 569.3m

Total Rating: -7.89 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 46.95

1. Piotroski 4.50pt = -0.50

2. FCF Yield 0.26% = 0.13

3. FCF Margin 3.26% = 0.82

4. Debt/Equity 0.15 = 2.49

5. Debt/Ebitda 3.06 = -1.85

6. ROIC - WACC (= -36.28)% = -12.50

7. RoE -25.07% = -2.50

8. Rev. Trend 99.26% = 7.44

9. EPS Trend 68.37% = 3.42

What is the price of NTRA shares?

As of November 12, 2025, the stock is trading at USD 206.63 with a total of 1,452,760 shares traded.
Over the past week, the price has changed by +4.24%, over one month by +22.07%, over three months by +31.58% and over the past year by +54.24%.

Is Natera a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Natera (NASDAQ:NTRA) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 46.95 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NTRA is around 235.32 USD . This means that NTRA is currently undervalued and has a potential upside of +13.88% (Margin of Safety).

Is NTRA a buy, sell or hold?

Natera has received a consensus analysts rating of 4.48. Therefore, it is recommended to buy NTRA.

Strong Buy: 12
Buy: 8
Hold: 0
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the NTRA price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	219.8	6.4%
Analysts Target Price	219.8	6.4%
ValueRay Target Price	270.6	31%

NTRA Fundamental Data Overview November 10, 2025

Market Cap USD = 27.54b (27.54b USD * 1.0 USD.USD)
P/S = 13.0126
P/B = 17.6447
Beta = 1.643
Revenue TTM = 2.12b USD
EBIT TTM = -316.8m USD
EBITDA TTM = -280.1m USD
Long Term Debt = 106.8m USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 80.3m USD (from shortTermDebt, last quarter)
Debt = 184.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -856.7m USD (from netDebt column, last quarter)
Enterprise Value = 26.69b USD (27.54b + Debt 184.7m - CCE 1.04b)
Interest Coverage Ratio = -72.48 (Ebit TTM -316.8m / Interest Expense TTM 4.37m)
FCF Yield = 0.26% (FCF TTM 69.1m / Enterprise Value 26.69b)
FCF Margin = 3.26% (FCF TTM 69.1m / Revenue TTM 2.12b)
Net Margin = -14.61% (Net Income TTM -309.2m / Revenue TTM 2.12b)
Gross Margin = 63.70% ((Revenue TTM 2.12b - Cost of Revenue TTM 768.4m) / Revenue TTM)
Gross Margin QoQ = 64.91% (prev 63.50%)
Tobins Q-Ratio = 14.65 (Enterprise Value 26.69b / Total Assets 1.82b)
Interest Expense / Debt = 0.57% (Interest Expense 1.04m / Debt 184.7m)
Taxrate = -0.24% (negative due to tax credits) (207.0k / -87.3m)
NOPAT = -317.6m (EBIT -316.8m * (1 - -0.24%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 3.27 (Total Current Assets 1.45b / Total Current Liabilities 442.0m)
Debt / Equity = 0.15 (Debt 184.7m / totalStockholderEquity, last quarter 1.25b)
Debt / EBITDA = 3.06 (negative EBITDA) (Net Debt -856.7m / EBITDA -280.1m)
Debt / FCF = -12.40 (Net Debt -856.7m / FCF TTM 69.1m)
Total Stockholder Equity = 1.23b (last 4 quarters mean from totalStockholderEquity)
RoA = -16.97% (Net Income -309.2m / Total Assets 1.82b)
RoE = -25.07% (Net Income TTM -309.2m / Total Stockholder Equity 1.23b)
RoCE = -23.64% (EBIT -316.8m / Capital Employed (Equity 1.23b + L.T.Debt 106.8m))
RoIC = -24.29% (negative operating profit) (NOPAT -317.6m / Invested Capital 1.31b)
WACC = 11.99% (E(27.54b)/V(27.73b) * Re(12.07%) + D(184.7m)/V(27.73b) * Rd(0.57%) * (1-Tc(-0.00)))
Discount Rate = 12.07% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 7.23%
[DCF Debug] Terminal Value 54.71% ; FCFE base≈69.1m ; Y1≈45.4m ; Y5≈20.7m
Fair Price DCF = 1.77 (DCF Value 243.6m / Shares Outstanding 137.5m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 68.37 | EPS CAGR: 149.9% | SUE: -1.53 | # QB: 0
Revenue Correlation: 99.26 | Revenue CAGR: 44.00% | SUE: 3.26 | # QB: 11

Additional Sources for NTRA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle